Shattuck Labs, Inc. (STTK) Free cash flow
- Free cash flow · 12 months (USD): Value $-41.24M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -4124.00%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-41.24M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-41.03M − $212.00K ≈ $-41.24M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -4124.00% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-41.24M ÷ $1.00M × 100 ≈ -4124.00% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-41.03M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.78× | Operating cash flow / net income. Period ending 2026-06-30. $-41.03M ÷ $-52.57M ≈ 0.78× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -41.03M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 212.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -41.24M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -52.57M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-41.24M | (m) | $-41.03M | $212.00K | (m) | $1.00M | (m) | $-52.57M | (m) | (m) | -4124.00% | 0.78× |
| 2026-03-31 | (m) | (m) | $-41.27M | (m) | (m) | $1.00M | (m) | $-49.87M | (m) | (m) | (m) | 0.83× |
| 2025-12-31 | $-39.95M | (m) | $-39.88M | $71.00K | (m) | $1.00M | (m) | $-48.81M | (m) | (m) | -3995.30% | 0.82× |
| 2025-09-30 | $-48.83M | (m) | $-48.76M | $71.00K | (m) | $1.00M | (m) | $-54.90M | (m) | (m) | -4883.30% | 0.89× |
| 2025-06-30 | $-55.94M | (m) | $-55.90M | $42.00K | (m) | $3.00M | (m) | $-61.51M | (m) | (m) | -1866.57% | 0.91× |
| 2025-03-31 | (m) | (m) | $-56.39M | (m) | (m) | $4.61M | (m) | $-70.61M | (m) | (m) | (m) | 0.80× |
| 2024-12-31 | $-60.57M | (m) | $-60.52M | $59.00K | (m) | $5.72M | (m) | $-75.41M | (m) | (m) | -1058.80% | 0.80× |
| 2024-09-30 | $-62.64M | (m) | $-62.56M | $76.00K | (m) | $6.43M | (m) | $-74.42M | (m) | (m) | -973.43% | 0.84× |
| 2024-06-30 | $-63.28M | (m) | $-63.23M | $53.00K | (m) | $4.12M | (m) | $-85.28M | (m) | (m) | -1534.51% | 0.74× |
| 2024-03-31 | $-71.26M | (m) | $-70.93M | $332.00K | (m) | $2.71M | (m) | $-85.08M | (m) | (m) | -2624.68% | 0.83× |
| 2023-12-31 | $-81.64M | (m) | $-81.23M | $407.00K | (m) | $1.66M | (m) | $-87.30M | (m) | (m) | -4926.67% | 0.93× |
| 2023-09-30 | $-86.73M | (m) | $-85.65M | $1.08M | (m) | $1.33M | (m) | $-95.02M | (m) | (m) | -6506.60% | 0.90× |
| 2023-06-30 | $-98.80M | (m) | $-96.98M | $1.81M | (m) | $859.00K | (m) | $-92.12M | (m) | (m) | -11501.28% | 1.05× |
| 2023-03-31 | $-103.88M | (m) | $-94.68M | $9.20M | (m) | $709.00K | (m) | $-98.14M | (m) | (m) | -14652.05% | 0.96× |
| 2022-12-31 | $-106.11M | (m) | $-94.50M | $11.61M | (m) | $652.00K | (m) | $-101.94M | (m) | (m) | -16274.85% | 0.93× |
| 2022-09-30 | $-102.28M | (m) | $-89.37M | $12.91M | (m) | $30.34M | (m) | $-68.69M | (m) | (m) | -337.13% | 1.30× |
| 2022-06-30 | $-87.43M | (m) | $-74.30M | $13.13M | (m) | $32.03M | (m) | $-61.46M | (m) | (m) | -272.97% | 1.21× |
| 2022-03-31 | $-80.10M | (m) | $-72.33M | $7.78M | (m) | $27.75M | (m) | $-57.69M | (m) | (m) | -288.68% | 1.25× |
| 2021-12-31 | $-65.04M | (m) | $-57.12M | $7.93M | (m) | $30.02M | (m) | $-44.97M | (m) | (m) | -216.68% | 1.27× |
| 2021-09-30 | $-58.58M | (m) | $-52.44M | $6.14M | (m) | $1.28M | (m) | $-64.83M | (m) | (m) | -4572.91% | 0.81× |
| 2021-06-30 | $-56.07M | (m) | $-50.80M | $5.27M | (m) | $1.82M | (m) | $-59.25M | (m) | (m) | -3087.56% | 0.86× |
| 2021-03-31 | $-37.53M | (m) | $-34.27M | $3.26M | (m) | $9.23M | (m) | $-41.86M | (m) | (m) | -406.71% | 0.82× |
| 2020-12-31 | $-34.39M | (m) | $-33.66M | $727.00K | (m) | $9.93M | (m) | $-36.60M | (m) | (m) | -346.14% | 0.92× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-27.09M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-21.45M | (m) | $-20.98M | $470.00K | (m) | $9.89M | (m) | $-23.98M | (m) | (m) | -216.90% | 0.87× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |